Moderna (MRNA) Scheduled to Post Quarterly Earnings on Thursday

Moderna (NASDAQ:MRNA) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.93) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Moderna Stock Down 2.0 %

Shares of NASDAQ MRNA opened at $53.54 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The firm has a market capitalization of $20.58 billion, a price-to-earnings ratio of -3.48 and a beta of 1.69. The stock has a 50 day moving average price of $64.05 and a 200 day moving average price of $100.65. Moderna has a 52-week low of $52.26 and a 52-week high of $170.47.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,184 shares of company stock valued at $238,531. Corporate insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on MRNA shares. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Leerink Partners lowered their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Jefferies Financial Group lowered their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Sanford C. Bernstein assumed coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price for the company. Finally, TD Cowen lowered their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $94.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.